The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Abstract
PURPOSE: Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may attain complete remissions when treated with transfusions of leukocytes obtained from the original bone marrow donor. We performed a retrospective study to characterize better this new treatment modality. PATIENTS AND METHODS: We surveyed 25 North American BMT programs regarding their use of donor leukocyte infusions (DLI). Detailed forms were used to gather data regarding the original BMT, relapse, DLI, response to DLI, complications of DLI, and long-term follow-up evaluation. Reports of 140 patients were thus available for analysis. RESULTS: Complete responses were observed in 60% (95% confidence interval [CI], 51.9% to 68.1%) of chronic myelogenous leukemia (CML) patients who received DLI and did not receive pre-DLI chemotherapy; response rates were higher in patients with cytogenetic and chronic-phase relapse (75.7%; 95% CI, 68.2% to 83.2%) than in patients with accelerated-phase (33.3%; 95% CI, 19.7% to 46.9%) or blastic-phase (16.7%; 95% CI, 1.9% to 31.9%) relapse. The actuarial probability of remaining in complete remission at 2 years was 89.6%. Complete remission rates in acute myelogenous leukemia (AML) (n = 39) and acute lymphocytic leukemia (ALL) (n = 11) patients who had not received pre-DLI chemotherapy were 15.4% (95% CI, 9.6% to 21.2%) and 18.2% (95% CI, 6.6% to 29.8%), respectively. Complete remissions were also observed in two of four assessable myeloma patients and two of five assessable myelodysplasia patients. Complications of DLI included acute graft-versus-host disease (GVHD) (60%; 95% CI, 51.4% to 68.6%), chronic GVHD (60.7%; 95% CI, 50.3% to 71.1%), and pancytopenia (18.6%; 95% CI, 12.2% to 25.0%). Pre-DLI characteristics predictive of complete response in CML patients were post-BMT chronic GVHD, pre-DLI disease status of chronic phase, and time interval between BMT to DLI less than 2 years. Acute and chronic GVHD post-DLI were highly correlated with disease response (P < .00001). CONCLUSION: DLI results in complete remissions in a high percentage of patients with relapsed chronic-phase CML. Complete remissions are observed less frequently in patients with advanced CML and acute leukemia. GVHD and pancytopenia occur commonly; GVHD is highly correlated with response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
GLUCKSBERG, H., STORB, R., FEFER, A., BUCKNER, C. D., NEIMAN, P. E., CLIFT, R. A., LERNER, K. G., & THOMAS, E. D. (1974) · Transplantation · doi:10.1097/00007890-197410000-00001 · Cited by 3,694
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Chronic graft-versus-host syndrome in man
Shulman, H. M., Sullivan, K. M., Weiden, P. L., McDonald, G. B., Striker, G. E., Sale, G. E., Hackman, R., Tsoi, M.-S., Storb, R., & Donnall Thomas, E. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90380-0 · Cited by 2,406
Kolb, H., Schattenberg, A., Goldman, J., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., & Niederwieser, D. (1995) · Blood · doi:10.1182/blood.v86.5.2041.bloodjournal8652041 · Cited by 1,934
Kolb, H., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M., & Wilmanns, W. (1990) · Blood · doi:10.1182/blood.v76.12.2462.2462 · Cited by 1,528
Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., Thomas, E. D., & The Seattle Marrow Transplant Team (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042507 · Cited by 1,081
Mackinnon, S., Papadopoulos, E., Carabasi, M., Reich, L., Collins, N., Boulad, F., Castro-Malaspina, H., Childs, B., Gillio, A., & Kernan, N. (1995) · Blood · doi:10.1182/blood.v86.4.1261.bloodjournal8641261 · Cited by 722
Graft-versus-myeloma effect: proof of principle
Tricot, G., Vesole, D., Jagannath, S., Hilton, J., Munshi, N., & Barlogie, B. (1996) · Blood · doi:10.1182/blood.v87.3.1196.bloodjournal8731196 · Cited by 543
Drobyski, W. R., KEEVER, C. A., Roth, M. S., Koethe, S., Hanson, G. A., McFadden, P. W., Gottschall, J., Ash, R., van Tuinen, P., & Horowitz, M. (1993) · Blood · doi:10.1182/blood.v82.8.2310.2310 · Cited by 346
Self-citation
Cited by
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Chronic graft-versus-host disease
Lee, S. J., Vogelsang, G., & Flowers, M. E. D. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2003.50026 · Cited by 950
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation
Socié, G., Stone, J. V., Wingard, J. R., Weisdorf, D., Henslee-Downey, P. J., Bredeson, C., Cahn, J.-Y., Passweg, J. R., Rowlings, P. A., Schouten, H. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410103 · Cited by 698
Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E., & Davis, M. M. (2000) · Nature Medicine · doi:10.1038/79526 · Cited by 672
Self-citationBrentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Schmid, C., Labopin, M., Nagler, A., Bornhäuser, M., Finke, J., Fassas, A., Volin, L., Gürman, G., Maertens, J., Bordigoni, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6053 · Cited by 516
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500
Self-citationNatural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Ho, V. T., & Soiffer, R. J. (2001) · Blood · doi:10.1182/blood.v98.12.3192 · Cited by 426
Marijt, W. A. E., Heemskerk, M. H. M., Kloosterboer, F. M., Goulmy, E., Kester, M. G. D., van der Hoorn, M. A. W. G., van Luxemburg-Heys, S. A. P., Hoogeboom, M., Mutis, T., Drijfhout, J. W., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530192100 · Cited by 408
Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2955 · Cited by 403
Graft-versus-leukemia reactions in allogeneic chimeras
Kolb, H.-J., Schmid, C., Barrett, A. J., & Schendel, D. J. (2004) · Blood · doi:10.1182/blood-2003-02-0342 · Cited by 397
Molecules and mechanisms of the graft-versus-leukaemia effect
Bleakley, M., & Riddell, S. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1365 · Cited by 392
Platzbecker, U., Wermke, M., Radke, J., Oelschlaegel, U., Seltmann, F., Kiani, A., Klut, I.-M., Knoth, H., Röllig, C., Schetelig, J., et al. (2012) · Leukemia · doi:10.1038/leu.2011.234 · Cited by 389
Berger, C., Flowers, M. E., Warren, E. H., & Riddell, S. R. (2006) · Blood · doi:10.1182/blood-2005-08-3503 · Cited by 334
Baron, F., Maris, M. B., Sandmaier, B. M., Storer, B. E., Sorror, M., Diaconescu, R., Woolfrey, A. E., Chauncey, T. R., Flowers, M. E. D., Mielcarek, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.136 · Cited by 333
Godder, K. T., Henslee-Downey, P. J., Mehta, J., Park, B. S., Chiang, K.-Y., Abhyankar, S., & Lamb, L. S. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705650 · Cited by 306
CAR T cells: Continuation in a revolution of immunotherapy
Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303
Jenq, R. R., & van den Brink, M. R. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2804 · Cited by 299
Dazzi, F., Szydlo, R. M., Craddock, C., Cross, N. C. P., Kaeda, J., Chase, A., Olavarria, E., van Rhee, F., Kanfer, E., Apperley, J. F., et al. (2000) · Blood · doi:10.1182/blood.v95.1.67 · Cited by 290
Yan, C.-H., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Liu, Y.-R., Chen, H., Han, W., Wang, Y., Qin, Y.-Z., & Huang, X.-J. (2012) · Blood · doi:10.1182/blood-2011-09-380386 · Cited by 288
Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J., van Oers, M. H. J., Fibbe, W., Russell, I., Donk, N. W. C. J. V. D., & Verdonck, L. F. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3031 · Cited by 286
Immunotherapy through TCR gene transfer
Kessels, H. W. H. G., Wolkers, M. C., van den Boom, M. D., van den Valk, M. A., & Schumacher, T. N. M. (2001) · Nature Immunology · doi:10.1038/ni1001-957 · Cited by 279
Klein, J., Rizzo, J., Zhang, M.-J., & Keiding, N. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703260 · Cited by 278
Randolph, S. S. B., Gooley, T. A., Warren, E. H., Appelbaum, F. R., & Riddell, S. R. (2004) · Blood · doi:10.1182/blood-2003-07-2603 · Cited by 260
Transplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells
Brouwer, R. E., Zwinderman, K. H., Kluin-Nelemans, H. C., van Luxemburg-Heijs, S. A. P., Willemze, R., & Falkenburg, J. H. F. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(99)00143-5 · Cited by 46
Metadata
- Authors
- Collins, R. H., Shpilberg, O., Drobyski, W. R., Porter, D. L., Giralt, S., Champlin, R., Goodman, S. A., Wolff, S. N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J. H., & Nemunaitis, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-02
- Volume
- 15
- Issue
- 2
- Pages
- 433-444
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1873141201
- Cited by
- 1,237
- References
- 18
- FWCI
- 35.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.